September 23rd, 2024 (Shanghai) — We are glad to announce that Hong Seok Choi, Business Development of ABION, Inc., will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase from September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
About ABION, Inc.
ABION, INC, founded in 2007, is a biopharmaceutical company specializing in the development of innovative companion diagnostic-based new drugs that target the first-in-class/best-in-class categories of the global market. With continuous and diligent effort to make a progress, ABION has 81 registered patents, performed 41 government projects and is developing 12 pipelines including 1 pipeline in clinical trial phase II. Lately, we have received national grants from Korea Drug Development Fund (KDDF) for the development of ABN401 and 501. In 2021, ABION is listed in KOSDAQ for further expansion.
We have a wide and innovative collaboration with industrial partners, academic researchers, hospitals, and government. The synergism in collaboration facilitates the development of ABION’s pipelines. There are 4 major pipelines in the focus of oncology and infectious disease: ABN401 (vabametkib), ABN501, ABN202 and ABN101.
Our capability is to embark on a new innovative drug entity and validate through stringent protocols and consolidate proof of concept. With a strong standpoint of understanding unmet needs and discovering such new drug entity with deep consideration of precise medicine, we believe precision medicine would be the great assets for the public healthcare system. One of the critical thresholds is to find out the specific area of focus which could be hard to overlap with other company’s strategic plan, meaning it requires the networking and communication for further discussion about not only pipeline’s originality but also criticality of the public health system.
Our Main Pipeline
- Vabametkib(ABN401): Best-In-Class c-Met TKI for NSCLC Met dysregulation (Phase 2)
- ABN501: First-In-Class Claudin 3 human monoclonal antibody for pan-carcinoma target (Pre-clinical)
- ABN202: Unique Antibody-cytokine fusion engineering platform that targets Trop2 and EGFR
- ABN101: Broad-spectrum antiviral prophylaxis Inhaler drug (Pre-clinical)
About the speaker
Hong Seok Choi received his PhD in Microbiology and Immunology at the University of Florida in 2014. During his PhD, he studied the oncogenesis, lytic reactivation, and latency of Kaposi’s sarcoma herpesvirus (KSHV). Hong Seok Choi did his post-doctoral trainings at NCI/NIH in the United States, responsible for the research of KSHV infection in hypoxic environment; and at DVP/FDA, responsible for the study of broad-spectrum influenza vaccine. Then, he joined Abion Inc. in 2020, to develop Interferon-beta mutein as broad-spectrum anti-viral therapeutics. From 2023, he is also responsible for business development for all of Abion’s pipelines.
